Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $39.44 Average Target Price from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned an average rating of “Hold” from the eleven research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $39.4444.

Several research firms have recently issued reports on AGIO. Zacks Research upgraded shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 4th. The Goldman Sachs Group decreased their price target on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research note on Thursday, November 20th. Wall Street Zen cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Citigroup restated a “buy” rating on shares of Agios Pharmaceuticals in a report on Friday, December 26th. Finally, JPMorgan Chase & Co. raised their target price on Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, January 6th.

Insider Activity at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 18,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $506,664.27. Following the completion of the sale, the chief executive officer directly owned 136,583 shares in the company, valued at approximately $3,700,033.47. This trade represents a 12.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Tsveta Milanova sold 2,932 shares of the company’s stock in a transaction on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the completion of the transaction, the insider directly owned 29,190 shares in the company, valued at $790,757.10. This represents a 9.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 37,005 shares of company stock worth $1,064,531. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently modified their holdings of AGIO. NewEdge Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals during the first quarter valued at $40,000. First Horizon Corp acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth about $45,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Agios Pharmaceuticals by 16.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 320 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals in the third quarter worth about $79,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the first quarter worth about $133,000.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $27.17 on Thursday. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The stock’s fifty day moving average is $28.51 and its 200-day moving average is $35.37. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -3.88 and a beta of 0.89.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The firm had revenue of $12.88 million during the quarter, compared to analyst estimates of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. Agios Pharmaceuticals’s revenue was up 43.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $16.22 EPS. Analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.